404 results on '"Auclin E"'
Search Results
2. Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort
3. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study
4. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study
5. Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report.
6. Rechallenge de l’immunothérapie par nivolumab pour un cancer épidermoïde du larynx en poursuite évolutive après échec des modalités conventionnelles de traitement : cas clinique CARE
7. OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC
8. P2.09-29 Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY)
9. P2.07-05 Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry
10. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial
11. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy
12. Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA
13. Les temps forts de l’ESMO 2016
14. Approche par intelligence artificielle de la prédiction de la récidive biologique après prostatectomie dans une population d’ascendance africaine
15. 1090P HER2 copy number variation in non-small cell lung cancer (NSCLC)
16. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)
17. P1.16-02 Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale
18. MA07.07 Clinical/Molecular Profile of Patients with Non-small Cell Lung Cancer (NSCLC) with Incidental Pathogenic Germline Variants Detected in cfDNA
19. EP08.02-149 Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab
20. EP03.01-012 Characterization of Lung Cancer in Patients With High Familial Aggregation of Cancer: Preliminary Data From the SCAN Study
21. OA13.04 Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study
22. EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront
23. EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront
24. P1.07-02 Personal and Family HiStory of CANcer in Patients with Non-small Cell Lung Cancer: Preliminary Data of the SCAN Study
25. P1.12-04 The FLARE score and circulating neutrophils are associated with poor Covid-19 outcomes in patients with thoracic cancers
26. 1158P Study of patients’ characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC
27. 1642P Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
28. 1594P Cancer mortality in young population and estimated radon areas in Spain
29. 1282P Activity of brigatinib based on genomic alterations detected on ctDNA at baseline and at progression in ALK inhibitor-naïve advanced ALK+ NSCLC from the ALTA-1L trial
30. EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront
31. 1158P Study of patients’ characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC
32. EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront
33. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)
34. Prise en charge des infections de chambres implantables à bacilles gram négatifs aérobies : une étude observationnelle monocentrique rétrospective
35. 37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer
36. 184P Association of tumor-associated neutrophils (TAN) with immunotherapy outcomes in patients in advanced non-small cell lung cancer
37. 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)
38. 83P Association of lung immune prognostic index (LIPI) with progression-free survival (PFS) in soft-tissue sarcoma (STS) patients treated with immunotherapy (IO) in early phase trials
39. 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations
40. 1268P Real-time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC
41. 41P Testosterone level and severity of COVID-19 infection in ambispective cohorts: The TESTOVID study
42. LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC [MA08.04]
43. Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront [FP07.06]
44. LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC [MA08.04]
45. Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront [FP07.06]
46. 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)
47. Spécificités cliniques et histologiques des récidives des carcinomes chromophobes après traitement chirurgical–étude UROCCR 136
48. 1450P Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
49. 942P Response to salvage chemotherapy with paclitaxel +/- cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
50. 625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.